For Q1 FY2026 (ended March 31, 2026), Corcept Therapeutics reported revenue of $164.9M, up 4.9% year-over-year. Net income was -$31.8M, a significant decline from the prior year, and operating income was -$49.6M. Diluted EPS was -$0.30, down 276.5% year-over-year. The company had cash of $108.7M and equity of $638.0M, with no long-term debt.
•Revenue increased 4.9% YoY to $164.9M.
•Net loss of $31.8M vs. net income in prior year.
•Operating loss of $49.6M, sharply lower than prior year.
•Diluted EPS of -$0.30, down 276.5% YoY.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Corcept Therapeutics Incorporated, a biopharmaceutical company provides the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism.
Its portfolio also includes a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis, and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. Incorporated in 1998, the company is headquartered in Redwood City, California.
What does Corcept Therapeutics (CORT) do and what are its main products?
Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its primary marketed product is Korlym, an oral medication approved for treating hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have either failed surgery or are not candidates for surgery. The company also has a pipeline of selective cortisol modulators, including relacorilant, which is being developed for hypercortisolism; miricorilant, currently in a Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and other modulators like nenocorilant and dazucorilant, the latter being investigated for Lou Gehrig's disease (ALS).
Where is Corcept Therapeutics (CORT) listed and what currency does it trade in?
Corcept Therapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CORT. The company trades in US Dollars (USD), reflecting its primary operations and headquarters in the United States. As a US-based biopharmaceutical company, its financial reporting and stock trading are conducted in USD, making it accessible to investors on major US exchanges.
What sector and industry does Corcept Therapeutics (CORT) belong to?
Corcept Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for serious medical conditions, leveraging its expertise in cortisol modulation. This industry involves research, development, and commercialization of drugs, often targeting unmet medical needs in endocrinology, oncology, metabolism, and neurology.
Where is Corcept Therapeutics (CORT) headquartered and what markets does it serve?
Corcept Therapeutics is headquartered in Redwood City, California, United States. The company primarily serves the US market, as indicated by its description focusing on operations within the United States. Its marketed product, Korlym, is available for patients in the US with Cushing's syndrome. While its pipeline may have global potential, the current commercial and clinical activities are centered in the US.
How does Corcept Therapeutics (CORT) generate revenue and what is its business model?
Corcept Therapeutics generates revenue primarily through the sale of its approved product, Korlym, which is an oral medication for treating hyperglycemia in patients with endogenous Cushing's syndrome. The company's business model is typical of a biopharmaceutical firm: it invests in research and development to discover and develop selective cortisol modulators, then commercializes them through its own sales and marketing efforts. Beyond Korlym, the company has a pipeline of drug candidates, including relacorilant, miricorilant, nenocorilant, and dazucorilant, which target various disorders such as hypercortisolism, metabolic dysfunction-associated steatohepatitis, and ALS. Future revenue may come from these candidates if they receive regulatory approval.